Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - UBS maintained its Buy rating and $9.00 price target on Lifestance Health Group (NASDAQ:LFST), citing significant upside potential of 68% for the healthcare technology company. According to InvestingPro data, analysts are highly bullish with a consensus recommendation of 1.38 (Strong Buy), with price targets ranging from $6.50 to $10.00.
The investment firm highlighted a disconnect between Lifestance’s performance and its current valuation, pointing to several key growth drivers including a revamped management team with a clear path to double-digit adjusted EBITDA growth and margin expansion.
UBS noted Lifestance’s proven clinician recruiting engine delivers consistent annual growth exceeding 10%, which enhances return on investment while additional growth opportunities are supported by a strong free cash flow profile and solid balance sheet with $189 million in cash against $273 million in debt.
The firm emphasized Lifestance operates in a large, underpenetrated market, with 2025 revenue estimated at approximately 1.2% of the $116 billion total addressable market.
At the current $6 stock price and 21x multiple, UBS believes the market is pricing in next-twelve-months adjusted EBITDA of approximately $105 million, which is more than 33% below the firm’s estimate, suggesting market expectations are overly conservative.
In other recent news, LifeStance Health Group reported its earnings for the second quarter of 2025, showing a narrower-than-expected loss and a slight revenue beat. The company announced an earnings per share of -$0.01, which was better than the anticipated -$0.03. Revenue reached $345 million, slightly exceeding the forecast of $345.05 million and marking an 11% increase compared to the previous year. In addition to its financial performance, LifeStance Health Group made changes to its board of directors. William Miller resigned from the board, with the company clarifying that his departure was not due to any disagreement. Following his resignation, Sarah Personette was appointed as a new director. Personette was granted 74,766 restricted stock units, which will vest based on time and performance criteria. These developments reflect the company’s ongoing adjustments and financial reporting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.